KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Humana (HUM) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Humana (HUM) over the last 17 years, with Q3 2025 value amounting to $5.4 billion.

  • Humana's Cash & Equivalents rose 531.67% to $5.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.4 billion, marking a year-over-year increase of 531.67%. This contributed to the annual value of $2.2 billion for FY2024, which is 5268.43% down from last year.
  • According to the latest figures from Q3 2025, Humana's Cash & Equivalents is $5.4 billion, which was up 531.67% from $4.0 billion recorded in Q2 2025.
  • Over the past 5 years, Humana's Cash & Equivalents peaked at $16.2 billion during Q2 2023, and registered a low of $2.2 billion during Q4 2024.
  • Moreover, its 5-year median value for Cash & Equivalents was $5.1 billion (2022), whereas its average is $6.6 billion.
  • As far as peak fluctuations go, Humana's Cash & Equivalents skyrocketed by 21500.93% in 2022, and later plummeted by 6622.66% in 2024.
  • Over the past 5 years, Humana's Cash & Equivalents (Quarter) stood at $3.4 billion in 2021, then surged by 49.12% to $5.1 billion in 2022, then fell by 7.25% to $4.7 billion in 2023, then crashed by 52.68% to $2.2 billion in 2024, then surged by 142.59% to $5.4 billion in 2025.
  • Its Cash & Equivalents was $5.4 billion in Q3 2025, compared to $4.0 billion in Q2 2025 and $4.2 billion in Q1 2025.